1
|
Comini G, Kelly R, Jarrin S, Patton T, Narasimhan K, Pandit A, Drummond N, Kunath T, Dowd E. Survival and maturation of human induced pluripotent stem cell-derived dopaminergic progenitors in the parkinsonian rat brain is enhanced by transplantation in a neurotrophin-enriched hydrogel. J Neural Eng 2024; 21:024002. [PMID: 38479026 DOI: 10.1088/1741-2552/ad33b2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/30/2023] [Accepted: 03/13/2024] [Indexed: 03/26/2024]
Abstract
Objective.Although human induced pluripotent stem cell (iPSC)-derived cell replacement for Parkinson's disease has considerable reparative potential, its full therapeutic benefit is limited by poor graft survival and dopaminergic maturation. Injectable biomaterial scaffolds, such as collagen hydrogels, have the potential to address these issues via a plethora of supportive benefits including acting as a structural scaffold for cell adherence, shielding from the host immune response and providing a reservoir of neurotrophic factors to aid survival and differentiation. Thus, the aim of this study was to determine if a neurotrophin-enriched collagen hydrogel could improve the survival and maturation of iPSC-derived dopaminergic progenitors (iPSC-DAPs) after transplantation into the rat parkinsonian brain.Approach.Human iPSC-DAPs were transplanted into the 6-hydroxydopamine-lesioned striatum either alone, with the neurotrophins GDNF and BDNF, in an unloaded collagen hydrogel, or in a neurotrophin-loaded collagen hydrogel.Post-mortem, human nuclear immunostaining was used to identify surviving iPSC-DAPs while tyrosine hydroxylase immunostaining was used to identify iPSC-DAPs that had differentiated into mature dopaminergic neurons.Main results.We found that iPSC-DAPs transplanted in the neurotrophin-enriched collagen hydrogel survived and matured significantly better than cells implanted without the biomaterial (8 fold improvement in survival and 16 fold improvement in dopaminergic differentiation). This study shows that transplantation of human iPSC-DAPs in a neurotrophin-enriched collagen hydrogel improves graft survival and maturation in the parkinsonian rat brain.Significance.The data strongly supports further investigation of supportive hydrogels for improving the outcome of iPSC-derived brain repair in Parkinson's disease.
Collapse
Affiliation(s)
- Giulia Comini
- Pharmacology & Therapeutics, University of Galway, Galway, Ireland
| | - Rachel Kelly
- Pharmacology & Therapeutics, University of Galway, Galway, Ireland
- Department of Biomedicine, Aarhus University, Aarhus, Denmark
| | - Sarah Jarrin
- Pharmacology & Therapeutics, University of Galway, Galway, Ireland
| | - Tommy Patton
- Pharmacology & Therapeutics, University of Galway, Galway, Ireland
| | | | - Abhay Pandit
- CÚRAM Centre for Research in Medical Devices, University of Galway, Galway, Ireland
| | - Nicola Drummond
- Centre for Regenerative Medicine, University of Edinburgh, Edinburgh, United Kingdom
| | - Tilo Kunath
- Centre for Regenerative Medicine, University of Edinburgh, Edinburgh, United Kingdom
| | - Eilís Dowd
- Pharmacology & Therapeutics, University of Galway, Galway, Ireland
| |
Collapse
|
2
|
Torres-Ortega PV, Del Campo-Montoya R, Plano D, Paredes J, Aldazabal J, Luquin MR, Santamaría E, Sanmartín C, Blanco-Prieto MJ, Garbayo E. Encapsulation of MSCs and GDNF in an Injectable Nanoreinforced Supramolecular Hydrogel for Brain Tissue Engineering. Biomacromolecules 2022; 23:4629-4644. [DOI: 10.1021/acs.biomac.2c00853] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Affiliation(s)
- Pablo Vicente Torres-Ortega
- Department of Pharmaceutical Technology and Chemistry, Faculty of Pharmacy and Nutrition, University of Navarra, C/Irunlarrea 1, 31008Pamplona, Spain
- Navarra Institute for Health Research, IdiSNA, C/Irunlarrea 3, 31008Pamplona, Spain
| | - Rubén Del Campo-Montoya
- Department of Pharmaceutical Technology and Chemistry, Faculty of Pharmacy and Nutrition, University of Navarra, C/Irunlarrea 1, 31008Pamplona, Spain
- Navarra Institute for Health Research, IdiSNA, C/Irunlarrea 3, 31008Pamplona, Spain
| | - Daniel Plano
- Department of Pharmaceutical Technology and Chemistry, Faculty of Pharmacy and Nutrition, University of Navarra, C/Irunlarrea 1, 31008Pamplona, Spain
- Navarra Institute for Health Research, IdiSNA, C/Irunlarrea 3, 31008Pamplona, Spain
| | - Jacobo Paredes
- Tecnun, School of Engineering, University of Navarra, C/Manuel de Lardizábal 15, 20018San Sebastián, Spain
| | - Javier Aldazabal
- Tecnun, School of Engineering, University of Navarra, C/Manuel de Lardizábal 15, 20018San Sebastián, Spain
| | - María-Rosario Luquin
- Navarra Institute for Health Research, IdiSNA, C/Irunlarrea 3, 31008Pamplona, Spain
- Department of Neurology and Neurosciences, Clínica Universidad de Navarra, Pamplona, C/Pío XII 36, 31008Pamplona, Spain
| | - Enrique Santamaría
- Clinical Neuroproteomics Unit, Navarrabiomed, Hospital Universitario de Navarra (HUN), Universidad Pública de Navarra (UPNA), Instituto de Investigación Sanitaria de Navarra (IdisNa), 31008Pamplona, Spain
| | - Carmen Sanmartín
- Department of Pharmaceutical Technology and Chemistry, Faculty of Pharmacy and Nutrition, University of Navarra, C/Irunlarrea 1, 31008Pamplona, Spain
- Navarra Institute for Health Research, IdiSNA, C/Irunlarrea 3, 31008Pamplona, Spain
| | - María J. Blanco-Prieto
- Department of Pharmaceutical Technology and Chemistry, Faculty of Pharmacy and Nutrition, University of Navarra, C/Irunlarrea 1, 31008Pamplona, Spain
- Navarra Institute for Health Research, IdiSNA, C/Irunlarrea 3, 31008Pamplona, Spain
| | - Elisa Garbayo
- Department of Pharmaceutical Technology and Chemistry, Faculty of Pharmacy and Nutrition, University of Navarra, C/Irunlarrea 1, 31008Pamplona, Spain
- Navarra Institute for Health Research, IdiSNA, C/Irunlarrea 3, 31008Pamplona, Spain
| |
Collapse
|
3
|
Del Campo-Montoya R, Luquin MR, Puerta E, Garbayo E, Blanco-Prieto M. Hydrogels for Brain Repair: Application to Parkinson's Disease. Expert Opin Drug Deliv 2022; 19:1521-1537. [PMID: 36240170 DOI: 10.1080/17425247.2022.2136161] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
INTRODUCTION Parkinson's disease is the second most common neurodegenerative disease. Currently, there are no curative therapies, with only symptomatic treatment available. One of the principal reasons for the lack of treatments is the problem of delivering drugs to the brain, mainly due to the blood-brain barrier. Hydrogels are presented as ideal platforms for delivering treatments to the brain ranging from small molecules to cell replacement therapies. AREAS COVERED The potential application of hydrogel-based therapies for Parkinson's disease is addressed. The desirable composition and mechanical properties of these therapies for brain application are discussed, alongside the preclinical research available with hydrogels in Parkinson's disease. Lastly, translational and manufacturing challenges are presented. EXPERT OPINION Parkinson's disease urgently needs novel therapies to delay its progression and for advanced stages, at which conventional therapies fail to control motor symptoms. Neurotrophic factor-loaded hydrogels with stem cells offer one of the most promising therapies. This approach may increase the striatal dopamine content while protecting and promoting the differentiation of stem cells although the generation of synapses between engrafted and host cells remains an issue to overcome. Other challenges to consider are related to the route of administration of hydrogels and their large-scale production, required to accelerate their translation toward the clinic.
Collapse
Affiliation(s)
| | | | | | - E Garbayo
- University of navarra, pamplona, 31008 spain
| | | |
Collapse
|
4
|
Elabi OF, Davies JS, Lane EL. L-dopa-Dependent Effects of GLP-1R Agonists on the Survival of Dopaminergic Cells Transplanted into a Rat Model of Parkinson Disease. Int J Mol Sci 2021; 22:ijms222212346. [PMID: 34830228 PMCID: PMC8618072 DOI: 10.3390/ijms222212346] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/24/2021] [Revised: 11/05/2021] [Accepted: 11/12/2021] [Indexed: 12/27/2022] Open
Abstract
Cell therapy is a promising treatment for Parkinson's disease (PD), however clinical trials to date have shown relatively low survival and significant patient-to-patient variability. Glucagon Like Peptide-1 receptor (GLP-1R) agonists have potential neuroprotective effects on endogenous dopaminergic neurons. This study explores whether these agents could similarly support the growth and survival of newly transplanted neurons. 6-OHDA lesioned Sprague Dawley rats received intra-striatal grafts of dopaminergic ventral mesencephalic cells from embryonic day 14 Wistar rat embryos. Transplanted rats then received either saline or L-dopa (12 mg/kg) administered every 48 h prior to, and following cell transplantation. Peripheral GLP-1R agonist administration (exendin-4, 0.5 μg/kg twice daily or liraglutide, 100 μg/kg once daily) commenced immediately after cell transplantation and was maintained throughout the study. Graft survival increased under administration of exendin-4, with motor function improving significantly following treatment with both exendin-4 and liraglutide. However, this effect was not observed in rats administered with L-dopa. In contrast, L-dopa treatment with liraglutide increased graft volume, with parallel increases in motor function. However, this improvement was accompanied by an increase in leukocyte infiltration around the graft. The co-administration of L-dopa and exendin-4 also led to indicators of insulin resistance not seen with liraglutide, which may underpin the differential effects observed between the two GLP1-R agonists. Overall, there may be some benefit to the supplementation of grafted patients with GLP-1R agonists but the potential interaction with other pharmacological treatments needs to be considered in more depth.
Collapse
Affiliation(s)
- Osama F. Elabi
- School of Pharmacy and Pharmaceutical Sciences, Cardiff University, Cardiff CF10 3NB, UK
- Correspondence: (O.F.E.); (E.L.L.)
| | - Jeffrey S. Davies
- Institute of Life Sciences, School of Medicine, Swansea University, Swansea SA2 8PP, UK;
| | - Emma L. Lane
- School of Pharmacy and Pharmaceutical Sciences, Cardiff University, Cardiff CF10 3NB, UK
- Correspondence: (O.F.E.); (E.L.L.)
| |
Collapse
|